{"id":8890,"date":"2025-10-10T17:18:26","date_gmt":"2025-10-10T14:18:26","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8890"},"modified":"2025-10-10T17:18:26","modified_gmt":"2025-10-10T14:18:26","slug":"anticoagulation-in-prosthetic-artificial-heart-valves","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/anticoagulation-in-prosthetic-artificial-heart-valves\/","title":{"rendered":"Anticoagulation in Prosthetic (Artificial) Heart Valves\u00a0"},"content":{"rendered":"<div>Anticoagulation in Prosthetic (Artificial) Heart Valves<\/div>\n<div><\/div>\n<div>(Based on ESC\/EACTS Guidelines 2021 and preliminary 2025 update highlights, ACC\/AHA 2020 Guidelines, and Recent Reviews 2024)<\/div>\n<div><\/div>\n<div>Keynotes:<\/div>\n<div>1-Mechanical Valves (Surgical)<\/div>\n<div><span> \u2022 Warfarin only \u2014 required lifelong for all mechanical valves.<\/span><\/div>\n<div><span> \u2022 DOACs are contraindicated (not allowed).<\/span><\/div>\n<div><span> \u2022 Target INR:<\/span><\/div>\n<div><span> \u2022 Aortic valve \u2192 2.5 (no risk factors) \/ 3.0 (with risk factors)<\/span><\/div>\n<div><span> \u2022 Mitral valve \u2192 3.0 (higher thrombotic risk)<\/span><\/div>\n<div><\/div>\n<div>Why Warfarin only?<\/div>\n<div><span> \u2022 Mechanical valves are made of metal or carbon surfaces that directly contact blood and strongly activate clotting.<\/span><\/div>\n<div><span> \u2022 Warfarin blocks several key clotting factors (II, VII, IX, X), giving broad protection against valve thrombosis and embolic stroke.<\/span><\/div>\n<div><span> \u2022 DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) inhibit only one target (thrombin or Xa) and were unsafe in the RE-ALIGN trial (NEJM 2013), showing higher thrombosis, stroke, and bleeding.<\/span><\/div>\n<div><span> \u2022 Therefore, DOACs are Class III \u2013 Harm in all guidelines; they must not be used for mechanical valves.<\/span><\/div>\n<div><\/div>\n<div>2-Bioprosthetic Valves (Surgical Tissue Valves)<\/div>\n<div><span> \u2022 Warfarin (INR \u2248 2.5) for 3\u20136 months, then switch to Aspirin only.<\/span><\/div>\n<div><span> \u2022 If bleeding risk is high \u2192 Aspirin alone from the start is acceptable.<\/span><\/div>\n<div><span> \u2022 After 6 months \u2192 Aspirin lifelong.<\/span><\/div>\n<div><span> \u2022 DOACs may be used only if the patient has another indication (e.g., atrial fibrillation), but not routinely.<\/span><\/div>\n<div><\/div>\n<div>3-Transcatheter valves (TAVR \/ TMVR \/ TTVR) cause less procedural trauma than surgical tissue valves:<\/div>\n<div><\/div>\n<div><span> \u2022 Aspirin only (Single Antiplatelet Therapy) is now preferred (Class IIa ,Level of Evidence)\u00a0<\/span><\/div>\n<div><span> \u2022 Short DAPT (Aspirin + Clopidogrel for \u2248 3 months) may be used in high-thrombotic-risk cases(Class IIb=optional)<\/span><\/div>\n<div><span> \u2022Warfarin or DOACs \u2014 Class IIb, and usually used if another condition requires them (e.g., atrial fibrillation, LV thrombus).<\/span><\/div>\n<div>Summary Statement :<\/div>\n<div>For Transcatheter Valves, Aspirin (SAPT) remains the standard (Class IIa).<\/div>\n<div>Short DAPT is optional (Class IIb).<\/div>\n<div>Oral anticoagulation (Warfarin \/ DOAC) is Class I if another indication exists, and Class IIb if considered without one.<\/div>\n<div><\/div>\n<div>4-If the patient has Atrial Fibrillation or another clear indication for anticoagulation<\/div>\n<div><span> \u2022 Use Warfarin or a DOAC if the valve is bioprosthetic (not mechanical).<\/span><\/div>\n<div><span> \u2022 If the valve is mechanical, always Warfarin \u2014 never DOACs.<\/span><\/div>\n<div><\/div>\n<div>5-Bridging Therapy (during surgery\/procedures):<\/div>\n<div><span> \u2022 Major surgery \u2192 interrupt VKA and bridge with heparin.<\/span><\/div>\n<div><span> \u2022 UFH (intravenous) preferred for predictable effect; LMWH acceptable if monitored (anti-Xa 0.5\u20131.0 U\/mL).<\/span><\/div>\n<div><span> \u2022 Fondaparinux should not be used (Class III).<\/span><\/div>\n<div><\/div>\n<div>Summary:<\/div>\n<div>U.S. guidelines (ACC\/AHA 2020) limit bridging to mitral or high-risk cases,<\/div>\n<div>while European guidelines (ESC 2021) recommend bridging for all mechanical valves.<\/div>\n<div><\/div>\n<div>Key Takeaway :<\/div>\n<div><span> \u2022 Mechanical valve \u2192 Warfarin lifelong (only proven safe).<\/span><\/div>\n<div><span> \u2022 Bioprosthetic surgical valve \u2192 short-term Warfarin or Aspirin, then Aspirin lifelong.<\/span><\/div>\n<div><span> \u2022 Transcatheter valve \u2192 Aspirin (\u00b1 short DAPT).<\/span><\/div>\n<div><span> \u2022 DOACs \u2192 only for other indications, and never for mechanical valves.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Valvular-Heart-Disease?\">https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/Valvular-Heart-Disease?<\/a><\/div>\n<div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anticoagulation in Prosthetic (Artificial) Heart Valves (Based on ESC\/EACTS Guidelines 2021 and preliminary 2025 update highlights, ACC\/AHA 2020 Guidelines, and Recent Reviews 2024) Keynotes: 1-Mechanical Valves (Surgical) \u2022 Warfarin only \u2014 required lifelong for all mechanical valves. \u2022 DOACs are contraindicated (not allowed). \u2022 Target INR: \u2022 Aortic valve \u2192 2.5 (no risk factors) \/ [&hellip;]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8890","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8890","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8890"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8890\/revisions"}],"predecessor-version":[{"id":8891,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8890\/revisions\/8891"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}